Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AM 411

Next Previous
Drug Profile

AM 411

Alternative Names: AM-411

Latest Information Update: 02 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Altamira Therapeutics
  • Class Antirheumatics; Peptides; Small interfering RNA
  • Mechanism of Action RELA protein expression modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Preclinical Rheumatoid arthritis

Most Recent Events

  • 02 Jan 2025 Altamira Therapeutics files a provisional patent application for nanoparticle-based circular RNA delivery platform(CycloPhore™)
  • 24 Sep 2024 Altamira Therapeutics plans to file an IND application to the US FDA for Rheumatoid arthritis, in 2026
  • 01 May 2024 Altamira Therapeutics files a provisional patent application with the USPTO which covers nanoparticles comprising OligoPhore™ platform and siRNA targeting the p65 protein

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top